MedTech Terms
    The authoritative reference
    All terms
    Investment & FinanceStartup LifecycleSBIR/STTR

    SBIR / STTR Grants

    U.S. federal small-business R&D grants from agencies including NIH and DoD.

    Reviewed by Christian Espinosa, Founder, Blue Goat CyberLast reviewed May 5, 2026

    Definition

    Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) are U.S. federal grant programs that fund early-stage R&D at small businesses. NIH, NSF, DoD, and BARDA are the most relevant agencies for MedTech. Phase I (~$300K) funds feasibility; Phase II (~$2M) funds prototype and validation. Award amounts and topics are set by each agency and published in its solicitations, so the figures above are typical rather than fixed. STTR also requires a formal partnership with a research institution.
    What the regulation says
    SBIR/STTR grants, while providing non-dilutive funding for MedTech innovation, fall outside the direct purview of typical regulatory frameworks like 21 CFR Part 820 for Quality System Regulation or ISO 13485 for Medical Devices, since they primarily concern funding mechanisms rather than product quality or safety. However, the R&D activities funded by these grants are still subject to relevant regulations and standards based on the nature of the medical device being developed, such as FDA design control requirements found in 21 CFR 820.30 during Phase II. Similarly, if clinical studies are involved, then Good Clinical Practice (GCP) guidelines, like those outlined by the ICH E6(R2) guideline, must be followed.

    What this means in practice

    Non-dilutive, retains IP with the small business, and signals scientific credibility. Highly competitive; success rates around 15–20% for NIH.

    Examples

    • A small business uses a Phase I SBIR grant to conduct feasibility studies for a novel diagnostic device, including preliminary assessments of user needs and potential hazards as part of an early risk management process.
    • A MedTech startup utilizes Phase II STTR funding to develop a prototype surgical tool and performs verification testing following a design plan, adhering to initial design control principles.
    • A company developing an AI-powered medical imaging tool uses SBIR funds to conduct performance studies, ensuring data integrity and algorithm validation in preparation for a future FDA premarket submission.
    Common pitfalls
    • •A common pitfall is misunderstanding that securing an SBIR/STTR grant automatically confers regulatory approval or streamlines the regulatory submission process.
    • •Another mistake is neglecting to integrate regulatory strategy and quality system considerations early in the R&D process, even during the grant-funded phases.
    • •Companies often fail to allocate sufficient grant funds and resources specifically for crucial regulatory activities, such as biocompatibility testing or electromagnetic compatibility (EMC) testing, which are necessary for eventual market authorization.
    • •Assuming that the technical success criteria for a grant are the same as the regulatory requirements for market clearance or approval can lead to significant delays.
    • •Mismanaging intellectual property generated during the grant project can create future regulatory and commercial challenges, despite the grants’ general policy of retaining IP with the small business.

    Frequently asked questions

    While the grant application itself doesn't typically demand full regulatory compliance documentation, strong proposals often include a well-considered regulatory strategy, especially for Phase II, demonstrating an understanding of the path to market.

    Related terms

    Grouped by theme
    Cited by

    Where this term appears across MedTech Terms.

    Ecosystems (1)

    Latest in MedTech

    Sources

    3 sources

    Sources support the definition or relevant regulatory context, not necessarily every claim on this page. Each is graded against our source-tier hierarchy so you can see what rests on binding law versus commentary.

    Tier 2Regulator guidance and consensus· 1Tier 3Peer-reviewed and registry evidence· 1Tier 4Trade press and expert commentary· 1
    Link health: 3 verified· last checked 2026-06-20
    SBIR.gov·1NIH·1NVCA·1
    1. 1
      SBIR.gov
      Tier 2 Verified
      SBIR.govsbir.gov
    2. 2
      NIH SEED
      Tier 3 Verified
      NIHseed.nih.gov
    3. 3
      NVCA Model Documents
      Tier 4 Verified
      NVCAnvca.org

    Inline markers like [1] jump to the matching reference above.